In line with these findings, we have recently reported that targeting CI arrests progression of osteosarcomas, converting them into low-proliferative, oncocytoma-like lesions, and demonstrated that the loss of hypoxia inducible factor 1-alpha (HIF-1α) is accountable for the antitumorigenic effects of CI dysfunction [3]. The gene discussed is HIF1A; the disease is osteosarcoma.